Leukoaraiosis in patients with tirofiban before endovascular thrombectomy: A post hoc analysis of a multicentre randomized clinical trial
There was no significant difference in disability severity at 90 days when treating AIS patients using intravenous tirofiban before endovascular therapy, in either absent-to-moderate or severe LA strata. It should be noted that intravenous tirofiban before endovascular therapy increases the incidence of radiologic intracranial hemorrhage in patients with severe LA.
Authors
- Zhizhou Hu (ORCID: https://orcid.org/0009-0004-0264-2055)
- Zhongming Qiu (ORCID: https://orcid.org/0000-0002-1622-9526)
- Fang Guo (ORCID: https://orcid.org/0000-0003-2847-3363)
- Qingwu Yang (ORCID: https://orcid.org/0000-0002-2596-2631)
- Chong Zheng (ORCID: https://orcid.org/0000-0001-8040-0511)
- Chaoxiong Shen
- Rongtong Li
Institutions
- Fujian Medical University (CN)
- Army Medical University (CN)
- Xinqiao Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Journal of the Formosan Medical Association
- Published
- 2024-08-22
- DOI
- https://doi.org/10.1016/j.jfma.2024.08.023
- Citations
- 2
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.10
Funders
- National Natural Science Foundation of China
- Army Medical University